首页> 外文期刊>European journal of pharmaceutical sciences >Development of novel fast-dissolving tacrolimus solid dispersion-loaded prolonged release tablet
【24h】

Development of novel fast-dissolving tacrolimus solid dispersion-loaded prolonged release tablet

机译:新型速溶他克莫司固体分散剂缓释片的研制

获取原文
获取原文并翻译 | 示例
           

摘要

The goal of this research was to develop a novel prolonged release tablet bioequivalent to the commercial sustained release capsule. A number of tacrolimus-loaded fast-dissolving solid dispersions containing various amounts of DOSS were prepared using the spray drying technique. Their solubility, dissolution and pharmacokinetics in rats were studied. DOSS increased drug solubility and dissolution in the solid dispersions. Compared with the drug powder, the solubility, dissolution and bioavailability of tacrolimus with the fast-dissolving solid dispersion containing tacrolimus/HP-p-CD/DOSS in the weight ratio of 5:40:4 were boosted by approximately 700-, 30- and 2-fold, respectively. Several tablet formulations were accomplished with this solid dispersion in combination with various ratios of HPMC/ethylcellulose. The release behaviour and pharmacokinetic studies in beagle dogs were assessed compared with the commercial prolonged release capsule. A decrease in HPMC/ethylcellulose ratios reduced the dissolution of tacrolimus from the tablets. Particularly, the tacrolimus-loaded prolonged release tablet consisting of fast-dissolving tacrolimus solid dispersion, HPMC, ethylcellulose and talc at the weight ratio of 20:66:112:2 exhibited a dissolution profile similar to that produced by the commercial prolonged release capsule. Furthermore, there were no significant differences in the AUC, C_(max) T_(max) and MRT values between them in beagle dogs. Consequently, this tacrolimus-loaded prolonged release tablet might be bioequivalent to the tacrolimus-loaded commercial capsule.
机译:这项研究的目的是开发一种生物等效于商业缓释胶囊的新型缓释片剂。使用喷雾干燥技术制备了许多载有他克莫司的载有不同量DOSS的他克莫司的速溶固体分散体。研究了它们在大鼠中的溶解度,溶解度和药代动力学。 DOSS增加了药物在固体分散体中的溶解度和溶解度。与药物粉末相比,以5:40:4的重量比包含他克莫司/ HP-p-CD / DOSS的速溶固体分散体,他克莫司的溶解度,溶解度和生物利用度提高了约700-,30-和2倍。将该固体分散体与各种比例的HPMC /乙基纤维素结合使用,可制成几种片剂。与商业延长释放胶囊相比,评估了比格犬的释放行为和药代动力学研究。 HPMC /乙基纤维素比例的降低减少了他克莫司从片剂中的溶解。特别地,由速溶他克莫司固体分散体,HPMC,乙基纤维素和滑石粉组成的重量比为20:66:112:2的他克莫司负载的缓释片剂显示出类似于由商业缓释胶囊产生的溶出曲线。此外,在比格犬中,它们之间的AUC,C_(max)T_(max)和MRT值之间无显着差异。因此,这种他克莫司负载的缓释片剂可能与他克莫司负载的商业胶囊具有生物等效性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号